Summary & Overview
HCPCS Level II J3150: Testosterone Propionate Injection, up to 100 mg
HCPCS Level II code J3150 denotes an injection of testosterone propionate, up to 100 mg, used in clinical settings for hormone therapy. The code is relevant for outpatient and ambulatory services where intramuscular medication administration occurs. Nationally, accurate coding for testosterone injections supports appropriate clinical documentation, billing integrity, and payer adjudication for hormone replacement and related therapies.
Key payers covered in this analysis include Aetna, Blue Cross Blue Shield, Cigna Health, UnitedHealthcare, and Medicare. Readers will find an overview of payer coverage patterns, typical sites of service, and common billing considerations associated with short-acting testosterone injections. The publication also outlines benchmarks for coding practice, relevant policy updates that affect HCPCS Level II drug billing, and clinical context for use of testosterone propionate.
This resource is intended to inform coding professionals, billing managers, and clinicians about the clinical meaning of J3150, common administrative considerations when reporting this HCPCS Level II code, and expected areas of payer review. Data not available in the input.
Billing Code Overview
HCPCS Level II code J3150 represents an injection of testosterone propionate, up to 100 mg. This code denotes a medication administration service for a short-acting testosterone ester formulated for intramuscular injection.
-
Service type: Medication injection (hormone therapy)
-
Typical site of service: Outpatient clinic, physician office, or ambulatory care setting where intramuscular injections are administered
Data not available in the input.
Clinical & Coding Specifications
Clinical Context
A 52-year-old male with confirmed primary hypogonadism presents to an outpatient endocrinology clinic for initiation of intramuscular testosterone therapy. The clinician documents low morning serum total testosterone on two separate occasions and symptoms of low libido, fatigue, and decreased muscle mass. After shared decision-making, the provider discontinues topical therapy and orders intramuscular testosterone propionate injections due to patient preference and tolerability. The nursing staff administers J3150 (Injection, testosterone propionate, up to 100 mg) intramuscularly in the clinic following standard injection-site assessment, informed consent, and verification of correct medication, dose, and lot. The workflow includes medication preparation, patient education on expected effects and adverse events, administration (typically into the gluteal or deltoid muscle), post‑injection observation for immediate adverse reaction, and documentation of lot number, expiration date, site of injection, and the administering clinician or nurse. Follow-up visits include monitoring of serum testosterone, hematocrit, prostate-specific antigen as appropriate, and assessment for efficacy and adverse effects.
Coding Specifications
| Modifier | Description | When to Use |
|---|---|---|
25 | Significant, separately identifiable evaluation and management service by the same physician on the same day of the procedure | Use when an E/M visit is performed on the same day as administration and is distinct from the injection visit |